Michigan spin-off Alertwatch gains FDA clearance to sell its patient monitoring services.
Alertwatch, a medtech spin-out of the University of Michigan, has received clearance from the US Food and Drug Administration (FDA) to begin selling its patient monitoring services to hospitals.
The start-up, which raised $1m last year for application to the FDA, displays easy-to-read data on patients during surgery. Its monitoring software draws on a range of sources to identify whether there any complications, and flashes up potential warnings and critical failures as amber and red alerts to surgeons.
Justin Adams, chief executive at Alertwatch, said: “We’ve had a lot of interest from clinicians who have seen the demo. Now that we’re over the FDA hurdle, it’ll be great to get the product into their hands.”
